Pfizer’s (PFE) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Pfizer (NYSE:PFE) in a research note released on Wednesday, Benzinga reports. They currently have a $45.00 target price on the biopharmaceutical company’s stock.

Other equities analysts have also recently issued research reports about the company. BMO Capital Markets reissued an outperform rating and issued a $36.00 price target (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Argus cut Pfizer from a buy rating to a hold rating in a research note on Friday, March 22nd. Finally, Morgan Stanley lifted their target price on Pfizer from $28.00 to $29.00 and gave the company an equal weight rating in a research note on Thursday, May 2nd. Ten investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Pfizer has a consensus rating of Hold and a consensus target price of $35.86.

Pfizer Trading Up 0.7 %

Shares of PFE opened at $27.99 on Wednesday. The business’s 50-day moving average price is $27.90 and its 200 day moving average price is $27.69. The stock has a market capitalization of $158.61 billion, a P/E ratio of -466.50, a P/E/G ratio of 1.08 and a beta of 0.70. Pfizer has a 1-year low of $25.20 and a 1-year high of $37.80. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The firm had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. Pfizer’s revenue was down 19.5% on a year-over-year basis. During the same quarter last year, the business posted $1.23 EPS. Analysts expect that Pfizer will post 2.38 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be paid a $0.42 dividend. The ex-dividend date of this dividend is Friday, July 26th. This represents a $1.68 annualized dividend and a dividend yield of 6.00%. Pfizer’s payout ratio is -2,800.00%.

Institutional Investors Weigh In On Pfizer

Several institutional investors and hedge funds have recently added to or reduced their stakes in PFE. Mather Group LLC. lifted its holdings in shares of Pfizer by 35.0% during the third quarter. Mather Group LLC. now owns 34,169 shares of the biopharmaceutical company’s stock worth $1,133,000 after buying an additional 8,857 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Pfizer by 97.8% during the third quarter. Tower Research Capital LLC TRC now owns 183,802 shares of the biopharmaceutical company’s stock worth $6,097,000 after buying an additional 90,896 shares during the last quarter. Cape Cod Five Cents Savings Bank lifted its holdings in shares of Pfizer by 103.6% during the third quarter. Cape Cod Five Cents Savings Bank now owns 57,884 shares of the biopharmaceutical company’s stock worth $1,920,000 after buying an additional 29,459 shares during the last quarter. Teza Capital Management LLC acquired a new position in shares of Pfizer during the third quarter worth approximately $347,000. Finally, Ironwood Investment Counsel LLC lifted its holdings in shares of Pfizer by 4.9% during the third quarter. Ironwood Investment Counsel LLC now owns 40,639 shares of the biopharmaceutical company’s stock worth $1,348,000 after buying an additional 1,913 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.